Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

被引：0
|
作者：
Bertani, E. [1 ]
Chiappa, A. [1 ]
Fazio, N. [1 ]
Grana, C. [1 ]
Bodei, L. [1 ]
Falconi, M. [2 ]
Ravizza, D. [1 ]
Spada, F. [1 ]
Andreoni, B. [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
[2] Univ Politecn Marche, Pancreas Surg Unit, Ancona, Italy
来源：
NEUROENDOCRINOLOGY | 2014年 / 99卷 / 3-4期
关键词：
neuroendocrine tumors; peptide receptor radionuclide therapy; surgery; survival; progression-free survival;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O2
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [31] The role of cytokines and their polymorphisms in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs): mini review
    Berkovic, Maja Cigrovski
    Jokic, Mladen
    Zjacic-Rotkvic, Vanja
    Kapitanovic, Sanja
    PERIODICUM BIOLOGORUM, 2007, 109 (02) : 111 - 114
  • [32] Reduced efficacy of repeated peptide receptor radionuclide therapy (PRRT) in progressive gastroenteropancreatic neuroendocrine tumours (GEP-NET)?
    Schnurr, J.
    Reimold, M.
    Dittmann, H.
    Kupferschlaeger, J.
    Bares, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S396 - S396
  • [33] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs): A United States Experience
    Katona, Bryson
    Riff, Brian
    Soulen, Michael
    Pryma, Daniel
    Bennett, Bonita
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina
    Metz, David
    PANCREAS, 2017, 46 (03) : 439 - 439
  • [34] PFS and OS After Salvage Peptide Receptor Radionuclide Therapy (PRRT) With 177-Lu[Dota0,Tyr3]octreotate in Patients With GastroEnteroPancreatic or Bronchial NeuroEndocrine Tumours (GEP-NETs): The Rotterdam Cohort
    van der Zwan, Wouter
    Brabander, Tessa
    Kam, Boen
    Teunissen, Jaap
    Krenning, Eric
    Kwekkeboom, Dik
    de Herder, Wouter
    PANCREAS, 2018, 47 (03) : 357 - 357
  • [35] Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
    Kanakis, George
    Kaltsas, Gregory
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2012, 26 (06) : 791 - 802
  • [36] mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
    Zanini, Sara
    Renzi, Serena
    Giovinazzo, Francesco
    Bermano, Giovanna
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [37] Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy
    van Vliet, Esther I.
    Teunissen, Jaap J. M.
    Kam, Boen L. R.
    de Jong, Marion
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    NEUROENDOCRINOLOGY, 2013, 97 (01) : 74 - 85
  • [38] Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors
    Tobias, Joseph
    Abou Azar, Sara
    Gujarathi, Rushabh
    Nordgren, Rachel
    Vaghaiwalla, Tanaz
    Millis, J. Michael
    Feinberg, Nicholas
    Liao, Chih-Yi
    Keutgen, Xavier M.
    SURGERY, 2025, 177
  • [39] The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Saif, Wasif M.
    Parikh, Rohan
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh P.
    Soares, Heloisa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] 177Lutetium-Peptide Receptor Radionuclide Therapy (PRRT) safety assessment in patients with refractory Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP NETs)
    van Bogaert, C.
    Mileva, M.
    Marin, G.
    Levillain, H.
    Artigas-Guix, C.
    Critchi, G.
    Marin, C.
    Hendlisz, A.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 161 - 161
12345